Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:

Subscribers log in here

Systemic lupus erythematosus in children


Systemic lupus erythematosus (SLE) in children is fundamentally the same disease as in adults with similar etiology, pathogenesis, clinical manifestations, and laboratory findings. However, the care of children and adolescents with SLE is very different from that of adults because of the impact of the disease and its therapy on physical and psychological growth and development. (See "Overview of the clinical manifestations of systemic lupus erythematosus in adults".)

Failure of therapy of childhood SLE frequently results from efforts to care for a child or adolescent with a complex and chronic disease without considering the special needs of the growing individual and his or her family. As a result, clinicians who are unprepared to deal with these needs should refer these patients to a pediatric rheumatology center.


The best estimate is that systemic lupus erythematosus (SLE) affects between 5000 and 10,000 children in the United States [1]. Childhood SLE affects girls more often than boys (8:1), even in the prepubescent age group (4:1). Although it can occur at any age, SLE becomes more frequent after five years of age and is increasingly prevalent after the first decade of life [2]. (See "Epidemiology and pathogenesis of systemic lupus erythematosus", section on 'Epidemiology'.)

Because the incidence and severity of childhood SLE vary by race, a comparison of data from institutions serving racially diverse populations is generally unrevealing [2]. Patients of Asian, African, or Latino ethnicity are all more frequently affected than Caucasians. Estimates of disease incidence between the ages of 10 and 18 in the United States among females of different ethnic groups are:

31 cases per 100,000 female Asians


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2014. | This topic last updated: Feb 19, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
  1. Lehman TJ. Systemic lupus erythematosus in children and adolescents. In: Dubois' Systemic Lupus Erythematosus, 5th ed, Wallace DA, Hahn B (Eds), WB Saunders, Philadelphia 1996.
  2. Lehman TJ, McCurdy DK, Bernstein BH, et al. Systemic lupus erythematosus in the first decade of life. Pediatrics 1989; 83:235.
  3. Huang JL, Yeh KW, Yao TC, et al. Pediatric lupus in Asia. Lupus 2010; 19:1414.
  4. Huang JL, Yao TC, See LC. Prevalence of pediatric systemic lupus erythematosus and juvenile chronic arthritis in a Chinese population: a nation-wide prospective population-based study in Taiwan. Clin Exp Rheumatol 2004; 22:776.
  5. Al-Arfaj AS, Al-Balla SR, Al-Dalaan AN, et al. Prevalence of systemic lupus erythematosus in central Saudi Arabia. Saudi Med J 2002; 23:87.
  6. Bader-Meunier B, Armengaud JB, Haddad E, et al. Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J Pediatr 2005; 146:648.
  7. Hiraki LT, Benseler SM, Tyrrell PN, et al. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 2008; 152:550.
  8. Watson L, Leone V, Pilkington C, et al. Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. Arthritis Rheum 2012; 64:2356.
  9. Livingston B, Bonner A, Pope J. Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus 2011; 20:1345.
  10. Arkachaisri T, Lehman TJ. Systemic lupus erythematosus and related disorders of childhood. Curr Opin Rheumatol 1999; 11:384.
  11. Yancey CL, Doughty RA, Athreya BH. Central nervous system involvement in childhood systemic lupus erythematosus. Arthritis Rheum 1981; 24:1389.
  12. Carbotte RM, Denburg SD, Denburg JA. Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis 1986; 174:357.
  13. Papero PH, Bluestein HG, White P, Lipnick RN. Neuropsychologic deficits and antineuronal antibodies in pediatric systemic lupus erythematosus. Clin Exp Rheumatol 1990; 8:417.
  14. Quintero-Del-Rio AI. Neurologic symptoms in children with systemic lupus erythematosus. J Child Neurol 2000; 15:803.
  15. Benseler SM, Silverman ED. Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus 2007; 16:564.
  16. Sibbitt WL Jr, Brandt JR, Johnson CR, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002; 29:1536.
  17. Olfat MO, Al-Mayouf SM, Muzaffer MA. Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus. Clin Rheumatol 2004; 23:395.
  18. Brunner HI, Ruth NM, German A, et al. Initial validation of the Pediatric Automated Neuropsychological Assessment Metrics for childhood-onset systemic lupus erythematosus. Arthritis Rheum 2007; 57:1174.
  19. Reichlin M, Broyles TF, Hubscher O, et al. Prevalence of autoantibodies to ribosomal P proteins in juvenile-onset systemic lupus erythematosus compared with the adult disease. Arthritis Rheum 1999; 42:69.
  20. Kiss E, Shoenfeld Y. Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus? Clin Rev Allergy Immunol 2007; 32:37.
  21. Hiraki LT, Feldman CH, Liu J, et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum 2012; 64:2669.
  22. Malleson PN. The role of the renal biopsy in childhood onset systemic lupus erythematosus: a viewpoint. Clin Exp Rheumatol 1989; 7:563.
  23. Al-Abbad AJ, Cabral DA, Sanatani S, et al. Echocardiography and pulmonary function testing in childhood onset systemic lupus erythematosus. Lupus 2001; 10:32.
  24. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49:193.
  25. Schmugge M, Revel-Vilk S, Hiraki L, et al. Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosus. J Pediatr 2003; 143:666.
  26. Seaman DE, Londino AV Jr, Kwoh CK, et al. Antiphospholipid antibodies in pediatric systemic lupus erythematosus. Pediatrics 1995; 96:1040.
  27. Descloux E, Durieu I, Cochat P, et al. Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies. Rheumatology (Oxford) 2008; 47:183.
  28. Stichweh D, Arce E, Pascual V. Update on pediatric systemic lupus erythematosus. Curr Opin Rheumatol 2004; 16:577.
  29. Richer O, Ulinski T, Lemelle I, et al. Abdominal manifestations in childhood-onset systemic lupus erythematosus. Ann Rheum Dis 2007; 66:174.
  30. Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, et al. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum 2007; 56:1966.
  31. Wright TB, Shults J, Leonard MB, et al. Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus. J Pediatr 2009; 155:260.
  32. Amital H, Szekanecz Z, Szücs G, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis 2010; 69:1155.
  33. Ruiz-Irastorza G, Egurbide MV, Olivares N, et al. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 2008; 47:920.
  34. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271.
  35. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64:2677.
  36. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349:1526.
  37. Lehman TJ. The clinical management of systemic lupus erythematosus in children and adolescents. In: The clinical management of systemic lupus erythematosus, 2nd ed, Schur PH (Ed), Lippincott-Raven, Philadelphia 1996.
  38. Lehman TJ. Modern treatment of childhood SLE. Clin Exp Rheumatol 2001; 19:487.
  39. Marks SD, Tullus K. Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. Acta Paediatr 2010; 99:967.
  40. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69:20.
  41. David J, Loftus J, Hesp R, et al. Spinal and somatic growth in patients with juvenile chronic arthritis treated for up to 2 years with deflazacort. Clin Exp Rheumatol 1992; 10:621.
  42. Guiducci C, Gong M, Xu Z, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010; 465:937.
  43. Buratti S, Szer IS, Spencer CH, et al. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001; 28:2103.
  44. Ravelli A, Ballardini G, Viola S, et al. Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus. J Rheumatol 1998; 25:572.
  45. Abud-Mendoza C, Sturbaum AK, Vazquez-Compean R, Gonzalez-Amaro R. Methotrexate therapy in childhood systemic lupus erythematosus. J Rheumatol 1993; 20:731.
  46. Mina R, von Scheven E, Ardoin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012; 64:375.
  47. McCurdy DK, Lehman TJ, Bernstein B, et al. Lupus nephritis: prognostic factors in children. Pediatrics 1992; 89:240.
  48. Lehman TJ, Sherry DD, Wagner-Weiner L, et al. Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr 1989; 114:1055.
  49. Lehman TJ. Long-term outcome of systemic lupus erythematosus in childhood. What is the prognosis? Rheum Dis Clin North Am 1991; 17:921.
  50. Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000; 136:243.
  51. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353:2219.
  52. Austin HA 3rd, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314:614.
  53. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 51:278.
  54. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350:971.
  55. Lehman TJ, Edelheit BS, Onel KB. Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis. Ann Rheum Dis 2004; 63:321.
  56. Aragon E, Chan YH, Ng KH, et al. Good outcomes with mycophenolate-cyclosporine-based induction protocol in children with severe proliferative lupus nephritis. Lupus 2010; 19:965.
  57. Kazyra I, Pilkington C, Marks SD, Tullus K. Mycophenolate mofetil treatment in children and adolescents with lupus. Arch Dis Child 2010; 95:1059.
  58. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005; 52:3168.
  59. Willems M, Haddad E, Niaudet P, et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006; 148:623.
  60. Podolskaya A, Stadermann M, Pilkington C, et al. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child 2008; 93:401.
  61. MacDermott EJ, Lehman TJ. Prospective, open-label trial of rituximab in childhood systemic lupus erythematosus. Curr Rheumatol Rep 2006; 8:439.
  62. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010; 62:2458.
  63. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62:222.
  64. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834.
  65. Lehman TJ, Singh C, Ramanathan A, et al. Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol Online J 2014; 12:3.
  66. Lisukov IA, Sizikova SA, Kulagin AD, et al. High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus. Lupus 2004; 13:89.
  67. Milanetti F, Abinun M, Voltarelli JC, Burt RK. Autologous hematopoietic stem cell transplantation for childhood autoimmune disease. Pediatr Clin North Am 2010; 57:239.
  68. Lehman TJ. A practical guide to systemic lupus erythematosus. Pediatr Clin North Am 1995; 42:1223.
  69. Ruperto N, Ravelli A, Cuttica R, et al. The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. Arthritis Rheum 2005; 52:2854.
  70. Brunner HI, Mina R, Pilkington C, et al. Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2011; 63:1213.
  71. Mina R, Klein-Gitelman MS, Ravelli A, et al. Inactive disease and remission in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012; 64:683.
  72. Taddio A, Rossetto E, Rosé CD, et al. Prognostic impact of atypical presentation in pediatric systemic lupus erythematosus: results from a multicenter study. J Pediatr 2010; 156:972.
  73. Otten MH, Cransberg K, van Rossum MA, et al. Disease activity patterns in juvenile systemic lupus erythematosus and its relation to early aggressive treatment. Lupus 2010; 19:1550.
  74. Platt JL, Burke BA, Fish AJ, et al. Systemic lupus erythematosus in the first two decades of life. Am J Kidney Dis 1982; 2:212.
  75. Glidden RS, Mantzouranis EC, Borel Y. Systemic lupus erythematosus in childhood: clinical manifestations and improved survival in fifty-five patients. Clin Immunol Immunopathol 1983; 29:196.
  76. Hagelberg S, Lee Y, Bargman J, et al. Longterm followup of childhood lupus nephritis. J Rheumatol 2002; 29:2635.
  77. Pereira T, Abitbol CL, Seeherunvong W, et al. Three decades of progress in treating childhood-onset lupus nephritis. Clin J Am Soc Nephrol 2011; 6:2192.
  78. Bartosh SM, Fine RN, Sullivan EK. Outcome after transplantation of young patients with systemic lupus erythematosus: a report of the North American pediatric renal transplant cooperative study. Transplantation 2001; 72:973.
  79. Spiera H, Rothenberg RR. Myocardial infarction in four young patients with SLE. J Rheumatol 1983; 10:464.